ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
61.78
-1.28 (-2.03%)
At close: 4:02PM EDT

61.78 0.00 (0.00%)
After hours: 5:44PM EDT

Stock chart is not supported by your current browser
Previous Close63.06
Open62.95
Bid61.01 x 800
Ask62.19 x 3000
Day's Range61.71 - 63.00
52 Week Range48.05 - 64.60
Volume5,764,376
Avg. Volume5,302,192
Market Cap108.312B
Beta1.73
PE Ratio (TTM)231.39
EPS (TTM)0.27
Earnings DateJul 18, 2018
Forward Dividend & Yield1.12 (1.83%)
Ex-Dividend Date2018-07-12
1y Target Est68.94
Trade prices are not sourced from all markets
  • Barrons.com3 days ago

    [$$] Look Who's Buying Verizon and JPMorgan

    Astute readers of Barron’s are familiar with investment firm Dalton Greiner Hartman Maher, which we’ve profiled a number of times, most recently about two years ago. DGHM, which has investments across all market capitalizations, has a reputation for expertise in finding value in smaller, lesser-known names. In fact, $1.2 billion of the total assets of $1.9 billion that the firm manages is invested in its DGHM V2000 SmallCap Value strategy, which launched in 1994.

  • Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?
    Zacks4 days ago

    Can Established Pharmaceuticals Up Abbott (ABT) Q2 Earnings?

    According to Abbott (ABT), key emerging markets represent the most attractive long-term growth opportunities for its branded generics product portfolio within EPD.

  • Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?
    Zacks4 days ago

    Can Medical Devices Strength Drive Abbott (ABT) Q2 Earnings?

    Abbott (ABT) poised to gain on continued growth in Medical Devices business in Q2.

  • Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves
    PR Newswire4 days ago

    Abbott Receives FDA Approval for Next-Generation MitraClip® Device to Treat People with Leaky Heart Valves

    ABBOTT PARK, Ill., July 12, 2018 /PRNewswire/ -- Abbott (ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

  • Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?
    Zacks5 days ago

    Can Abbott (ABT) Rise on Robust Overall Growth in Q2 Earnings?

    Abbott (ABT) gains traction from a steady healthy growth trajectory seen in core Diabetes Care business.

  • ACCESSWIRE6 days ago

    EX-Dividend Schedule: Abbott Laboratories Announced its 378th Consecutive Dividend; Will Trade Ex-Dividend on July 12, 2018

    LONDON, UK / ACCESSWIRE / July 10, 2018 / Active-Investors has a free review on Abbott Laboratories (NYSE: ABT) ("Abbott") following the Company's announcement that it will begin trading ex-dividend on July 12, 2018. To capture the dividend payout, investors must purchase the stock a day prior to the ex-dividend date that is by latest at the end of the trading session on July 11, 2018. Active-Investors has initiated due-diligence on this dividend stock.

  • CNBC7 days ago

    There may be politics but there is no debate: Breastfeeding is the best health option

    The Trump administration is in a political battle over breastfeeding guidance from the World Health Organization. The medical science is clear, and many studies and organizations support it: Breastfeeding offers health benefits to infants that last throughout childhood. Formula is a viable alternative that provides all the critical nutrients, but it cannot match some of the health properties found in mother's milk.

  • Why BioLife Solutions Stock Rose ~49% Last Week
    Market Realist7 days ago

    Why BioLife Solutions Stock Rose ~49% Last Week

    On July 6, BioLife Solutions (BLFS) stock closed at $17.02, ~508% higher than its 52-week low of $2.80 on July 7, 2017. After BioLife’s July 2 announcement of its Q2 2018 results, its stock rose ~31.38% to $14.99 from $11.41 the day before. On July 3, the stock rose ~11.41% to close at $16.70. Last Friday, BioLife stock rose ~49% week-over-week to $17.02 from $11.41.

  • Trump Today: President blasts NATO allies, Pfizer and China ahead of Supreme Court decision
    MarketWatch7 days ago

    Trump Today: President blasts NATO allies, Pfizer and China ahead of Supreme Court decision

    President Donald Trump on Monday sent out attacks on various targets over Twitter ahead of the announcement of his nominee for the Supreme Court.

  • Benzinga7 days ago

    Health Care Sector Outlook: Checking In Ahead Of Q2 Earnings Reports

    Throughout most of 2018, the health care sector’s performance has been moving in line with the S&P 500 (SPX). For Q2, the S&P 500 health care sector is expected to report 9.8 percent year-over-year earnings growth and 5.9 percent revenue growth, according to FactSet. Some uncertainty was removed when President Trump announced in May his administration’s plans to reduce drug prices.

  • Top Stocks Set to Disrupt the Diabetes Market
    Motley Fool10 days ago

    Top Stocks Set to Disrupt the Diabetes Market

    Revolutionary new drugs and medical devices could make these companies smart additions to your portfolio.

  • See what the IHS Markit Score report has to say about Abbott Laboratories.
    Markit10 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $1.96 billion.

  • Here's Why AbbVie Stock is Good for Your Portfolio's Health
    Zacks11 days ago

    Here's Why AbbVie Stock is Good for Your Portfolio's Health

    Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.

  • See what the IHS Markit Score report has to say about Abbott Laboratories.
    Markit11 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $1.96 billion.

  • ACCESSWIRE11 days ago

    Free Technical Research on Abbott Laboratories and Three More Medical Equipment Equities

    On Tuesday, July 03, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Tuesday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Viveve Medical Inc. (NASDAQ: VIVE), Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), and Align Technology Inc. (NASDAQ: ALGN). On Tuesday, shares in Englewood, Colorado headquartered Viveve Medical Inc. recorded a trading volume of 213,805 shares.

  • ETF Trends17 days ago

    Medical Device ETFs Still Look Healthy

    Medical device stocks and the related ETFs are among the brightest spots in the broader healthcare sector this year. iShares U.S. Medical Devices ETF (NYSEArca: IHI), the largest dedicated medical devices ...

  • Investopedia17 days ago

    Interested In Pharmaceutical Stocks? Try Novartis (ADR)

    The pharmaceutical industry is the cornerstone of modern medicine in the modern capitalist world, and it is a key component to a well-diversified stock portfolio. The Novartis of today was created through a series of mergers and acquisitions, the most recent being AveXis ( AVXS) for $8.7 billion in April 2018. The company can trace its history back to the mid-18 th and 19 th centuries to two Swiss companies: CIBA, founded in 1859, and J.R. Geigy Ltd., founded in 1758.

  • See what the IHS Markit Score report has to say about Abbott Laboratories.
    Markit18 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $442 million.

  • The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
    Zacks19 days ago

    The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

    The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M

  • CNBC19 days ago

    Stocks making the biggest moves in the premarket: CAG, PF, GIS, TEVA, WWE & more

    The food producer has reached a deal to buy Pinnacle Foods PF for $10.9 billion in cash and stock , with an implied value of $68 per share. General Mills GIS – General Mills reported fourth-quarter adjusted profit of 79 cents per share , 7 cents a share above estimates. The food producer said it expected a “dynamic” market environment in fiscal 2019, and sees organic net sales flat to up one percent in the new fiscal year.

  • Medtronic Announced a 9% Increase in Its Cash Dividend
    Market Realist20 days ago

    Medtronic Announced a 9% Increase in Its Cash Dividend

    On June 22, Medtronic (MDT) announced a 9% increase in its quarterly cash dividend to $0.50 per common share. The rise translates to an annual amount of $2.00 per common share.

  • Top Stock Reports for Facebook, Amgen & Abbott
    Zacks20 days ago

    Top Stock Reports for Facebook, Amgen & Abbott

    Top Stock Reports for Facebook, Amgen & Abbott

  • Abbott Announces Freedom 2 Save Program for Employees to Address Student Debt
    PR Newswire20 days ago

    Abbott Announces Freedom 2 Save Program for Employees to Address Student Debt

    ABBOTT PARK, Ill., June 26, 2018 /PRNewswire/ -- Historic levels of student debt have forced many people to choose between saving for their futures and paying off school loans. Abbott's Freedom 2 Save program will enable full-time and part-time employees who qualify for the company's 401(k) – and who are also contributing 2 percent of their eligible pay toward student loans – to receive an amount equivalent to the company's traditional 5 percent "match" deposited into their 401(k) plans. The benefit responds to recent financial challenges facing young employees – many of whom have undergraduate and advanced degrees in science, engineering and business fields – and adds to the strong appeal of joining the Abbott family.